// App-Quantinova.ai

: A Phase Ib Study of the Safety and Efficacy of Venetoclax When Combined with Escalating Doses of Omacetaxine in Patients with Relapsed/Refractory Acute Myeloid Leukemia Failing Treatment with Venetoclax-Containing Regimens (VEN-OM)

Researchers

Presenter

  • ana Maria Avila

Principal Investigators

  • Saad Arain

  • Karen Sweiss

  • Pritesh Patel

  • Samin Houshyar

  • Gregory S Calip

  • Irum Khan

  • Paul G. Rubinstein

  • Chukwuemeka Uzoka

  • John G. Quigley

Medical Centers

  • Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL

  • Division of Hematology/Oncology, University of Illinois, College of Medicine, Chicago, IL

  • Division of Internal Medicine, University of Illinois at Chicago, Chicago, IL

  • Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL

  • Division of Hematology/Oncology, Department of Medicine, University of Illinois Hospital & Health Sciences System, Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Nephrology

  • Oncology (ONC)

Disease

  • Disseminated intravascular coagulation

  • Acute myelocytic leukemia

  • Nephrotoxicity

  • Acute renal failure

  • Solid malignancies

Biomarkers

  • Angiomodulin

  • Hepatitis A virus cellular receptor 1

  • TIMP Metallopeptidase Inhibitor 2

Drug/Treatment

  • Omacetaxine mepesuccinate

  • Venetoclax

  • TIMP-2

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Adaptive

  • Open Label

  • Single Arm

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved